Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

Alexion wants to buy Swedish rare diseases biotech Wilson Therapeutics for around $855 million, which is developing a late-stage drug to treat the inherited condition Wilson Disease. In a statemen ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Alexion studies rare diseases, including two in the rare neurology space: generalized myasthenia gravis (gMG), which causes muscle weakness, and neuromyelitis optica spectrum disorder (NMOSD ...

At Alexion, AstraZeneca Rare Disease, we are committed to continuing to investigate the potential role of the complement system in various diseases and accelerating the discovery and development o ...

The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+ ...

Lauren Drouin is the director of analytical development and the Genomic Medicine Unit at Alexion AstraZeneca Rare Disease. As a dynamic scientist with unique expertise in current research and industry ...

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

so that people in Ontario with rare diseases have the best health outcomes possible." "Alexion Canada applauds Ontario for advancing rare disease care by signing the National Strategy for Drugs for ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25 th Annual ...